Sept 12, 2023
Prof Ho presented TLC-ART work at IAS in Brisbane last July. TLC-ART has proposed the transformation of the short-acting HIV treatment, TLD (Tenofovir, Lamivudine, Dolutegravir), into a long-acting, single-injection formula that is stable in vivo and in nonhuman primates. This new formulation addresses “pill fatigue” and offers consistent treatment effects lasting over four weeks. This advancement paves the way for more efficient HIV treatments and a potential new standard in patient care.
Contact: tlcart@uw.edu
